MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3 and 11. In a Phase I study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption.
INTRODUCTION
Despite many advances in the management of acute leukemia, patients with acute myelogenous leukemia (AML) who are refractory to conventional therapy, or who have relapsed after conventional therapy, have a poor prognosis for survival. In addition, the inability to tolerate or benefit from induction chemotherapy due to advanced age or co-morbidities is associated with poor clinical outcomes. Novel therapeutic strategies focusing on tumor-related alterations in chromatin structure and epigenetic silencing are currently being explored.
In eukaryotic cells, histone acetylation/deacetylation has an important role in the control of gene transcription regulation 1 . Transcriptionally active genes are characterized by hyperacetylated chromatin, while repressed genes are typically in a hypoacetylated state 2, 3 . This process is mediated by a complex interplay of proteins with histone acetyltransferases and deacetylases 2, 3 . Histone deacetylases (HDACs) are divided into 4 general classes. Class I includes HDACs 1, 2, 3 and 8. Class II HDACs 4, 5, 6, 7, 9 and 10. Class III includes Sirt 1 to 7; the latter group of enzymes is not targeted by HDAC inhibitors 4, 5 . Class IV includes HDAC 11,  which is distinct among the other classes.
Small molecule inhibitors of HDACs are a novel therapeutic class of drugs with anticancer potential 6 . Although not fully understood, the clinical activity of these inhibitors is thought to be mediated in part by induction of histone acetylation, resulting in a permissive or more open chromatin configuration and potential reactivation of aberrantly suppressed genes (e.g.
tumor suppressor genes). The changes in gene expression lead to inhibition of cell proliferation, induction of apoptosis and/or cell differentiation 7 .
HDAC inhibitors can be grouped into different subclasses, such as hydroxamic acids [8] [9] [10] [11] and aminophenylbenzamides 12, 13 based on their chemical structure. MGCD0103 is an isotype-specific aminophenylbenzamide that was synthesized through medicinal chemistry optimization of small molecule HDAC inhibitors. MGCD0103 inhibits HDAC isotypes 1, 2, 3, and 11 14, 15 .
This greater selectivity allows for targeting of the HDAC isotypes that are thought to be linked to cancer. Indeed, the number of genes with expression induced by MGCD0103 is dramatically smaller than that induced by non-specific hydroxamate HDAC inhibitors, yet efficacy in preclinical cancer models is maintained or increased (Fournel et al, submitted). Therefore, we hypothesize that the selective targeting of specific HDAC isotypes by MGCD0103 may improve the therapeutic window in cancer patients.
Preclinical studies have demonstrated that MGCD0103 is orally bioavailable with significant in vitro antineoplastic activity at sub-micromolar concentrations against a broad spectrum of human cancers, including various leukemia cell lines and xenografts 16 (Fournel et al submitted). Of importance, the half life of histone acetylation after MGCD0103 exposure in animals and in patient peripheral blood mononuclear cells (PBMCs) appears to outlasts pharmacokinetic (PK) exposure 16 . This prolonged pharmacodynamic (PD) effect appears to allow for less frequent dosing of MGCD0103. Based on this information, we conducted this open-label, nonrandomized, dose-escalation, multi-center Phase I trial of oral MGCD0103 administered three times a week in patients with leukemia and myelodysplastic syndromes (MDS).
MATERIALS AND METHODS
The objectives of the study were to assess the safety and tolerability of increasing doses of MGCD0103 when administered to patients with acute or chronic leukemia or MDS, and to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs). Secondarily, the clinical activity, effects on several potential clinical biomarkers, and PK characteristics of the compound were also evaluated in this patient population. This study was approved by all IRBs at MD Anderson Cancer Center, Jewish General Hospital and Princess Margaret Hospital. The study was performed following the principles of the Declaration of Helsinki. The study is registered at clinicaltrials.gov as NCT00324129.
Patient Selection
Patients enrolled in this study were ≥18 years of age with a diagnosis of relapsed or refractory AML, chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), or 
MDS (WHO classification criteria

Study Treatment
The active pharmaceutical ingredient of MGCD0103 was prepared by Torcan (Toronto, Canada), and the drug product was prepared by Patheon (Toronto, Ontario, Canada). Finished drug product was provided in 2 mg, 10 mg, and 25 mg gelcaps. Patients were instructed to take the intended dose orally 3 times per week on an every other day schedule with 200 mL of a low pH beverage, e.g., carbonated drinks. A cycle was defined as 21 days. The initial dose level was 20 mg/m 2 .
The MTD was defined as the maximum dose at which less than 2 out of 6 patients experienced a DLT. If 1 of 3 patients experienced a DLT at a specified dose level, 3 more patients were treated at that dose to confirm that the DLT was not observed in > 1 of 6 patients.
If 0 of 3 or 1 of 6 patients experienced a DLT, accrual began at the next higher dose level. All patients that received 1 dose of drug were evaluable for the safety and PK assessments, and all toxicity assessment for DLT occurred with respect to the first cycle of therapy. For the purpose of DLT and MTD determination each patient was counted once, at their initial assigned dose.
All patients who received at least 1 cycle of therapy were eligible for response assessment unless disease progression had occurred. Patients were allowed to receive supportive and palliative care
as clinically indicated throughout the study. The following treatments were not permitted during the study: other anti-cancer treatment including chemotherapy and radiotherapy, other investigational therapy or anti-neoplastic agents, or growth factor support for prophylactic use or as a substitute for a scheduled dose reduction.
Toxicities were graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. Leukemia-specific blood/bone marrow toxicity was used to classify hematological toxicity. Non-hematologic DLT was defined as any drug-related ≥ Grade 3 non-hematologic toxicity, except for Grade 3 nausea, vomiting, or diarrhea associated with suboptimal premedication and/or management, ≤ Grade 3 ALT for > 7
consecutive days, or any drug-associated toxic effect leading to 2 or more missed doses per cycle, or any drug-associated toxic effect resulting in the delay of the subsequent cycle by > 7 consecutive days. Hematologic DLT was defined as prolonged myelosuppression after therapy administration defined by an absolute neutrophil count of ≤ 500 k/μL and a platelet count of ≤ 30 k/μL with a bone marrow cellularity ≤ 5% without evidence of leukemia involvement lasting for more than 42 days.
Response criteria
Response was assessed using bone marrow aspirates collected pre-treatment and before the end of cycle 2, or as clinically indicated. A complete response (CR) required an absolute neutrophil count of ≥ 1 x 10 9 /L, platelet count of ≥ 100 x 10 9 /L, no blasts in the peripheral blood, bone marrow cellularity of ≥ 20% with normal trilineage maturation, bone marrow blasts ≤ 5% and absence of extramedullary involvement. PR was considered if there was normalization of peripheral blood counts as for CR, and the complete disappearance of peripheral blasts was observed with > 5%, but < 25% blasts in the marrow. A complete marrow response was considered if marrow blasts were ≤5% independent of peripheral counts..
Pharmacokinetic evaluation
The Plasma was aliquoted and stored at ≤ -40 °C. Samples were analyzed using a validated HPLC/MS method with a detection limit of 0.5 ng/mL. Plasma concentrations of MGCD0103 versus time profiles were generated, and PK parameters were derived using noncompartmental methods with WinNonlin® Professional (Pharsight Corp., Mountain View, California). The following PK parameters were determined: maximum times (T max , h) and maximum concentrations (C max , ng/mL) of drug in plasma, area under the plasma concentration-time curve (AUC 0-24h , ng*h/mL), and elimination half-life of drug in plasma (t ½ , h).
Isolation of human mononuclear cells
Blood Human PBMCs were separated using standard procedures.
Histone acetylation
Histone acetylation analysis, by enzyme-linked immunosorbant assay (ELISA), was performed using nuclear lysate or acid precipitated extracts from patient peripheral white cells. 
Statistical Methods
PK parameters were calculated based on actual blood sample collection times.
MGCD0103 plasma concentrations and PK parameters were summarized using descriptive statistics.
RESULTS
Patient characteristics
In all, 29 patients were enrolled in this study between February 2005 and July 2006.
Patient characteristics are shown in Table 1 . All 29 patients were eligible for the safety and PK analyses; only 23 patients were eligible for response assessment due to intercurrent illness (3 patients), toxicity (1 patient), or investigator/patient request (2 patients). Patients not eligible for the efficacy evaluation were removed from the study early during the first cycle of treatment. PK parameters were calculated for 27 patients. The most common diagnosis was AML in 22 patients (76%), followed by MDS in 5 patients (17%). Two other patients presented with either ALL or CML. Twenty-four (83%) patients had > 1 previous chemotherapy regimen including 4 patients (14%), who had also undergone allogeneic stem cell transplantation. Median age was 62 years (range 32 to 84 years). Cytogenetics were diploid in 11 of 29 (38%) patients, and abnormal in the 18 of 29 (62%) patients, including 2 patients with t(8;21) and 1 with t(9;22).
MGCD0103 dose escalation and toxicities
The most frequently reported adverse events were fatigue (22 / Non-hematological drug-related adverse events are also listed in Table 2 . Fatigue (7 patients) and abdominal pain (2 patients) were the most common Grade 3 (severe) nonhematological drug-related toxicities observed in patients receiving MGCD0103. Grade 3 nausea, vomiting, or diarrhea occurred in 1 patient each. There were no Grade 4 (life-threatening) nonhematological drug-related adverse events.
Clinical activity
Twenty-three patients were evaluable for efficacy. One patient receiving 60 mg/m 2 and 2 patients initially receiving 80 mg/m 2 followed by a dose reduction to 60 mg/m 2 achieved a complete bone marrow response ( Table 3 Table 3 . Of the three responders, 1 patient had refractory anemia with excess blasts (RAEB) and had received no prior therapy, and the other 2 patients had refractory AML and had received prior chemotherapy. For 2 of the responding patients the cytogenetics were diploid, and were complex for the other responding patient. The 2 patients initiated at the 80 mg/m 2 dose of MGCD0103 were subsequently reduced to 60 mg/m 2 for the majority of their treatment period due to gastrointestinal toxicity. The total duration of therapy ranged from 4-5 cycles for responders. Therapy was eventually discontinued in the responding patients for disease progression or lack of correction of peripheral blood counts. MGCD0103 plasma PK parameters are presented in Figure 2 and Supplemental Table 1 . An evaluation of PK exposure across all MGCD0103 Phase I studies was performed (data not shown) comparing predicted exposure (based on actual dose given) with body surface area (BSA). There was a minor trend toward inverse correlation between exposure and BSA.
However, this was insignificant relative to the inter-patient variability and is felt not to be clinically significant to predicting a given patient's likely exposure. In this evaluation, patients with a very low BSA (BSA ≤ 1.6) were not more likely to have excess drug exposure, while larger patients (BSA ≥ 2.2) were not more likely to be under-exposed. When the pharmacokinetic parameters AUC, or Cmax were compared in patients not experiencing first cycle DLT with patients experiencing first cycle DLT (Figures 3 A, B) , a clear correlation was not observed. However, the first cycle DLT in patients did correlate with the total daily dose they received ( Figure 3C ).
Histone acetylation and inhibition of whole cell HDAC enzyme activity
Histone H3 acetylation levels and whole cell HDAC enzyme activity were measured preand post-treatment in peripheral white cells as potential PD markers for MGCD0103 activity. In 
DISCUSSION
In preclinical studies, several structurally diverse HDAC inhibitors, including This study demonstrates that MGCD0103 administered orally three times a week is safe and active in patients with relapsed or refractory leukemia. Dose-limiting toxicities included primarily fatigue, nausea, vomiting and diarrhea, a symptom cluster that has been observed previously with this class of agents 11 . These toxicities, however, were non-life threatening and were effectively addressed by dosing delay and dose reduction. There were no Grade 4 drugrelated adverse events noted in this study. The MTD was 60 mg/m 2 with this dosing regimen, which is approximately equivalent to a 110 mg flat dose. The findings that the PK reached a plateau at higher doses, and that the incidence of DLTs tracked most closely with total daily dose rather than PK exposure, collectively suggest that unabsorbed drug may be limiting at very high doses.
We also demonstrated that MGCD0103 had favorable PK properties in this patient population with this dosing schedule. The drug was rapidly absorbed within 1 hour after oral administration, with a median T max ranging from 0.5 hour to 1.2 hours after single or multiple doses. Importantly, the drug had a long elimination half life in plasma of 9 hours, and remained quantifiable at 24 hours after a single dose. Drug exposure increased with doses up to 60 mg/m 2 , and then did not increase significantly with further increases in dose. PK exposure at the 60 mg/m 2 dose level exceeded the efficacious exposure in mouse xenograft models 16 . These properties, along with the biological effect of prolonged histone acetylation, allowed for the thrice weekly dosing schedule.
The PD activity of HDAC inhibition was explored in this study. In addition to the traditional method of measuring histone acetylation in cell lysates, a novel whole cell enzyme assay was developed in order to monitor HDAC activity in peripheral white cells obtained from the clinical setting 25 . This assay used a cell-permeable substrate with a fluorescent read-out, thus allowing evaluation of HDAC activity in live-cell populations. Considering the intricate complexity of transcriptional complexes that are disrupted in the process of measuring histone acetylation by traditional methods, this novel whole-cell HDAC activity assay maintains the integrity of these transcriptional and other protein-DNA complexes, and significantly contributes to the armamentarium of tools to study the PD effects of HDAC inhibitors. This assay has been validated in a variety of systems, and in patients with solid tumors, HDAC enzyme inhibition was dose-dependent and correlated well with drug accumulation in plasma 16, 25 19 . This PD/PK dissociation has implications for clinical trial development, as other schedules (daily or more prolonged exposure) may be beneficial. Studies examining these issues are ongoing. It is possible that cell selection, for example CD34 positive cells, may provide a more precise assessment of molecular effects secondary to therapy. Although using these cells is possible, prior Phase I studies conducted by our group have failed to detect differences between peripheral and bone marrow biomarker expression in patients with AML or high risk MDS 19, 26, 27 .
Clinical activity with MGCD0103 was observed in this population of patients with refractory, relapsed acute leukemia and MDS. Three patients on the study achieved a complete bone marrow response at doses of 60 mg/m 2 and above, suggesting a possible dose response at these levels. Of significance, 2 of the 3 responding patients had been previously treated with chemotherapy for refractory AML. The time to response observed in this study was 1-2 cycles, with the duration of response ranging from 1-3 cycles. All 3 patients had histone acetylation and HDAC inhibition as measured by the PD assays, but these limited observations could not necessarily be statistically correlated with response. Although preliminary, the single agent activity of this oral, isotype specific HDAC inhibitor in such a high risk, refractory population is notable and should be investigated further in efficacy trials.
In summary, we demonstrate that MGCD0103 is safe, and has clinical activity when administered orally as a single agent in patients with heavily pretreated AML, and in a patient with untreated INT-1 MDS. It is important to emphasize that MGCD0103 is highly selective for Author contribution: GGM and MM designed the study, wrote the manuscript, treated patients on study, and analyzed data. SA, JC, ZE, HK, WMN, and WM treated patients on study and analyzed data. HY, AK, JL, MD, TAP, ZL, JMB, GR, EL performed correlative studies and/or analyzed data. RM designed the study, analyzed data and wrote the manuscript.
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